Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients

A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients.

This phase II study is to evaluate the efficacy of SR-T100 gel in complete clearance of target warts at different concentrations (1.0% and 2.3% of SM in Solanum undatum plant extract) in patients with CW.

Study Overview

• Status: Suspended
• Conditions: Common Wart
• Intervention / Treatment: Drug: Vehicle gel; Drug: SR-T100 gel with 1.0% of SM; Drug: SR-T100 gel with 2.3% of SM

• Study Type: Interventional
• Enrollment (Estimated): 102
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 17 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age ≥ 17 years old.
2. The diagnosis of CW is based on visual inspection by an experienced dermatologist.
3. Patient is selected ≤ 5 CW lesions; each of the target lesion(s) needs to be ≤ 15 mm in diameter. For patient with only 1 selected lesion, the size of target lesion needs to be measuring 2 to 15 mm in diameter.
4. Patient agrees to apply the study medication on target CW lesion(s) with an occlusive dressing for at least 20 hours per day.
5. Patient or the legally acceptable representative of patient under 20 years of age, is willing and able to provide written informed consent.
6. Patient agrees not to use wart-removing product/modality (prescription or over-the-counter) other than the study product during the course of the study; and is willing to refrain from using cosmetics or other topical products in the treatment area for the duration of the study.
7. Any non-target CW receiving wart-removing procedures including cryotherapy and surgical therapy should be at least 5 cm apart from the target lesions.
8. Patient is free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk to the patient.
9. Patient is judged to be in good health based upon the results of physical examinations (PEs), medical history, and safety laboratory tests.
10. Patient in good general health condition (performance status ≤ 2 Eastern Cooperative Oncology Group (ECOG)).
11. Patient agrees to be photographed of the CW target lesion(s) and used of such data as part of the study package.
12. Female patient of childbearing potential should have a negative urine or serum pregnancy test at Screening day, and is willing to use effective contraception during the study.

Exclusion Criteria:

1. The treatment area is located in any of the following areas: the eye area (including eyelids), lips, mouth cavity, nasal cavity,inner ear, soles of the feet, underneath the nails, and the anogenital area.
2. Patient had participated in a clinical study within 30 days prior to the Randomization visit, or is currently participating in another clinical study.
3. Patient had used any wart-removing product/modality in the treatment area within 30 days prior to the Randomization visit or received cryotherapy in the treatment area within 60 days prior to the Randomization visit.
4. Patient who has immune-compromised conditions, have required or will require systemic intake of immunosuppressive or immunomodulatory medication (oral or parental corticosteroids are included) within 30 days prior to the Randomization visit or during the course of the study. Routine use of inhaled or intranasal corticosteroids during the study is allowed.

5. Patient has clinically significant or unstable medical conditions (psychologically and physically) in any of the following listed situations:

   1. Clinically significant peripheral vascular disease based on medical history.
   2. Current uncontrolled infection, current skin infections and/or skin disorder in the treatment area other than CW and/or in the area surrounding the warts that may confound or affect study assessment procedure of the study endpoints.
   3. Chronic or acute medical condition that, in the opinion of the investigator, may interfere with the study results or place the subject at undue risk (including human immunodeficiency virus, systemic lupus erythematosis, active viral hepatitis, etc.).
6. Patient is pregnant, plan to become pregnant, or is breastfeeding.
7. Patient has a history of allergy or sensitivity to Solanum undatum plant extract, SM, or SR-T100 gel excipients including carbomer, propylene glycol, and triethanolamine.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: vehicle gel; The vehicle gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.	Drug: Vehicle gel; Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
Active Comparator: SR-T100 gel with 1.0% of SM; SR-T100 contains 1.0% SM. The gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.	Drug: SR-T100 gel with 1.0% of SM; Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
Active Comparator: SR-T100 gel with 2.3% of SM; SR-T100 contains 2.3%SM. The gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.	Drug: SR-T100 gel with 2.3% of SM; Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Total clearance rate of treated CW	16 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of patient with at least 75% reduction in CW lesion counts		16 weeks
Proportion of patient with at least 50% reduction in lesion size (volume)		16 weeks
Mean of percent reduction in CW lesion counts from individual patient by visit		16 weeks
Mean of percent reduction in CW lesion size from individual patient by visit		16 weeks
CW recurrence rate		28 weeks
Time to complete clearance		16 weeks
Percent reduction for pooled lesion counts by visit		16 weeks
Safety: evaluate the changes occurring from baseline (Randomization visit) to EOT visit.	including PE, vital sign, lab. test, local skin reaction, and adverse event, etc.	28 weeks

Collaborators and Investigators

• Sponsor: G&E Herbal Biotechnology Co., LTD
• Investigators: Study Director: Kou-Wha Kuo, Ph.D, G&E Herbal Biotechnology Co., LTD; Principal Investigator: Hamm-Ming Sheu, MD, National Cheng-Kung University Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): September 1, 2030
• Primary Completion (Estimated): April 1, 2033
• Study Completion (Estimated): August 1, 2033

Study Registration Dates

• First Submitted: February 18, 2013
• First Submitted That Met QC Criteria: February 20, 2013
• First Posted (Estimated): February 22, 2013

Study Record Updates

• Last Update Posted (Actual): September 14, 2023
• Last Update Submitted That Met QC Criteria: September 13, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Keywords: common wart; verruca vulgaris
• Additional Relevant MeSH Terms: Skin Diseases; Virus Diseases; Infections; DNA Virus Infections; Skin Diseases, Infectious; Papillomavirus Infections; Skin Diseases, Viral; Tumor Virus Infections; Warts
• Other Study ID Numbers: GESRTCWA

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No